Format

Send to

Choose Destination
Alzheimers Dement. 2020 Jan;16(1):106-117. doi: 10.1002/alz.12033.

Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium.

Author information

1
Mayo Clinic, Rochester, Minnesota, USA.
2
University of California San Francisco, San Francisco, California, USA.
3
Case Western Reserve University, Cleveland, Ohio, USA.
4
University of California Los Angeles, Los Angeles, California, USA.
5
University of Pennsylvania, Philadelphia, Pennsylvania, USA.
6
Tau Consortium, Rainwater Charitable Foundation, Fort Worth, Texas, USA.
7
University of Washington, Seattle, Washington, USA.
8
Harvard University/Massachusetts General Hospital, Boston, Massachusetts, USA.
9
Association for Frontotemporal Degeneration, Radnor, Pennsylvania, USA.
10
National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD), Indiana University, Indianapolis, Indiana, USA.
11
University of North Carolina, Chapel Hill, North Carolina, USA.
12
Johns Hopkins University, Baltimore, Maryland, USA.
13
University of Toronto, Toronto, Ontario, Canada.
14
Washington University, St. Louis, Missouri, USA.
15
Columbia University, New York, New York, USA.
16
Mayo Clinic, Jacksonville, Florida, USA.
17
Northwestern University, Chicago, Illinois, USA.
18
University of British Columbia, Vancouver, British Columbia, Canada.
19
University of Texas Southwestern, Dallas, Texas, USA.
20
National Alzheimer Coordinating Center (NACC), University of Washington, Seattle, Washington, USA.
21
University of California San Diego, San Diego, California, USA.
22
National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, USA.
23
University of Alabama, Birmingham, Alabama, USA.
24
Bluefield Project, San Francisco, California, USA.
25
Laboratory of Neuroimaging (LONI), University of Southern California, Los Angeles, California, USA.

Abstract

INTRODUCTION:

We created global rating scoring rules for the CDR® plus NACC FTLD to detect and track early frontotemporal lobar degeneration (FTLD) and to conduct clinical trials in FTLD.

METHODS:

The CDR plus NACC FTLD rating was applied to 970 sporadic and familial participants from the baseline visit of Advancing Research and Treatment in Frontotemporal Lobar Degeneration (ARTFL)/Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS). Each of the eight domains of the CDR plus NACC FTLD was equally weighed in determining the global score. An interrater reliability study was completed for 40 participants.

RESULTS:

The CDR plus NACC FTLD showed very good interrater reliability. It was especially useful in detecting clinical features of mild non-fluent/agrammatic variant primary progressive aphasia participants.

DISCUSSION:

The global CDR plus NACC FTLD score could be an attractive outcome measure for clinical trials in symptomatic FTLD, and may be useful in natural history studies and clinical trials in FTLD spectrum disorders.

KEYWORDS:

CDR plus NACC FTLD; CDR®; behavior, comportment, and personality; frontotemporal lobar degeneration; global rating; language

PMID:
31914218
DOI:
10.1002/alz.12033

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center